Read news on anti-PD-L1 with our app.
Read more in the app
Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival - EurekAlert!
